July 13 (Reuters) - The U.S. FDA on Monday ‌approved an at-home starting dose of Eisai's and Biogen's Alzheimer's ‌drug, allowing some patients to begin therapy with injections administered by ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...

Shares of Biogen BIIB rose nearly 5% yesterday after the company announced that the FDA approved a subcutaneous (SC) autoinjector version of Leqembi as an initiation dosing option for the treatment of ...

What Is Leqembi, and Why Does It Matter? Leqembi (lecanemab) is a prescription medicine for Alzheimer's disease. This disease is a brain disorder that slowly destroys memory and thinking skills. Over ...

Eisai and Biogen won approval from the Food and Drug Administration for an injection of their Leqembi Iqlik drug as an initiation dose to treat early Alzheimer's disease. The companies said Monday the ...

The FDA has approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai Inc.), an amyloid-beta-directed antibody indicated for treating adult patients ...

Once-weekly 500 mg subcutaneous initiation is delivered by autoinjector as two 250 mg injections, allowing self- or caregiver administration at home rather than clinic-based IV starts. FDA acceptance ...

STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental ...